U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H11N
Molecular Weight 133.1903
Optical Activity ( - )
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of 1-AMINOINDANE, (R)-

SMILES

N[C@@H]1CCC2=C1C=CC=C2

InChI

InChIKey=XJEVHMGJSYVQBQ-SECBINFHSA-N
InChI=1S/C9H11N/c10-9-6-5-7-3-1-2-4-8(7)9/h1-4,9H,5-6,10H2/t9-/m1/s1

HIDE SMILES / InChI

Molecular Formula C9H11N
Molecular Weight 133.1903
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 10:52:05 GMT 2023
Edited
by admin
on Sat Dec 16 10:52:05 GMT 2023
Record UNII
I17RC77CJ2
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
1-AMINOINDANE, (R)-
Common Name English
((1R)-2,3-DIHYDRO-1H-INDEN-1-YL)AMINE
Systematic Name English
(1R)-2,3-DIHYDRO-1H-INDEN-1-AMINE
Systematic Name English
1H-INDEN-1-AMINE, 2,3-DIHYDRO-, (1R)-
Systematic Name English
1-AMINOINDAN, (-)-
Systematic Name English
(1R)-2,3-DIHYDRO-1H-INDENE-1-AMINE
Systematic Name English
TV-136
Code English
1-INDANAMINE, (R)-
Systematic Name English
(-)-1-AMINOINDAN
Systematic Name English
Code System Code Type Description
CAS
10277-74-4
Created by admin on Sat Dec 16 10:52:05 GMT 2023 , Edited by admin on Sat Dec 16 10:52:05 GMT 2023
PRIMARY
PUBCHEM
2733933
Created by admin on Sat Dec 16 10:52:05 GMT 2023 , Edited by admin on Sat Dec 16 10:52:05 GMT 2023
PRIMARY
EPA CompTox
DTXSID70370045
Created by admin on Sat Dec 16 10:52:05 GMT 2023 , Edited by admin on Sat Dec 16 10:52:05 GMT 2023
PRIMARY
FDA UNII
I17RC77CJ2
Created by admin on Sat Dec 16 10:52:05 GMT 2023 , Edited by admin on Sat Dec 16 10:52:05 GMT 2023
PRIMARY
Related Record Type Details
RACEMATE -> ENANTIOMER
Related Record Type Details
PARENT -> METABOLITE
major metabolite, 1(R)-aminoindan, which is not an MAO inhibitor, has been therapeutically active in animal models relevant to Parkinson?s disease
MAJOR
PLASMA